Pancreatic cancer has a big rate of mortality. In the US, about 38,000 cases yearly are fatal
Abraxane was previously approved to treat breast cancer in 2005 and lung cancer in 2012.
“We are pleased that patients with advanced pancreatic cancer now have a new treatment option helping to expand the treatment landscape for the fourth leading cause of cancer death in the United States,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network.
Abraxane’s producer, Celgene , is a successful company. Celgene’s total revenue last year was $ 5.5 billion, including sales for the multiple myeloma drug Revlimid.